From Wikipedia, the free encyclopedia
  (Redirected from Orelox)
Jump to navigation Jump to search
Clinical data
Trade names Generic (formerly Vantin)
AHFS/Drugs.com Monograph
MedlinePlus a698024
  • AU: B1
  • US: B (No risk in non-human studies)
Routes of
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability 50%
Protein binding 21% to 29%
Metabolism Negligible. Cefpodoxime proxetil is metabolized to cefpodoxime by the liver
Elimination half-life 2 hours
Excretion Renal, unchanged
CAS Number
PubChem CID
Chemical and physical data
Formula C15H17N5O6S2
Molar mass 427.458 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Cefpodoxime is an oral, third-generation cephalosporin antibiotic. It is active against most Gram-positive and Gram-negative organisms. Notable exceptions include Pseudomonas aeruginosa, Enterococcus, and Bacteroides fragilis. Currently, it is only marketed as generic preparations in the USA, according to the FDA Orange Book. It is commonly used to treat acute otitis media, pharyngitis, sinusitis, and gonorrhea. It also finds use as oral continuation therapy when intravenous cephalosporins (such as ceftriaxone) are no longer necessary for continued treatment.

Zoetis markets cefpodoxime proxetil under the trade name Simplicef for veterinary use. The dose range in dogs is 5–10 mg/kg body weight, administered orally, once a day.

Finecure, India markets the products under trade name Cefpo.[1]

Cefpodoxime inhibits cell wall synthesis by inhibiting the final transpeptidation step of peptidoglycan synthesis in cell walls. It has well established pharmacokinetic profile with absorption of 50%. It is indicated in community acquired pneumonia, uncomplicated skin and skin structure infections, and uncomplicated urinary tract infections.

Structural formula of cefpodoxime proxetil

Spectrum of bacterial susceptibility and resistance[edit]

Cefpodoxime has been used to fight pathogenic bacteria responsible for causing gonorrhoea, tonsillitis, pneumonia, and bronchitis. Representative pathogenic genera include Streptococcus, Haemophilus, and Neisseria. The following represents MIC susceptibility data for a few medically significant microorganisms.

  • Haemophilus influenzae: ≤0.03 - 1 μg/ml
  • Neisseria gonorrhoeae: 0.004 - 0.06 μg/ml
  • Streptococcus pyogenes: ≤0.004 - 2 μg/ml


Brand Name[edit]

Brand Name: Toraxim (Delta Pharma Ltd. Bangladesh), Trucef (by Renata Limited, Bangladesh).

Marketed Also As : Orelox By SanoFi-Aventis Pharma[3] MAPDOX-CV Cefpodoxime and Clavulanic acid combination

MONOTAX O (Cefpodoxime)/ MONOTAX CV (Cefpodoxime and Clavulanic acid combination)- Zydus Healthcare Ltd.


  1. ^ "Anti Biotics and Anti Bacterial". Finecurepharmaceuticalsltd. Retrieved 2012-03-27. 
  2. ^ http://www.toku-e.com/Assets/MIC/Cefpodoxime%20Free%20acid.pdf
  3. ^ "Orelox - Drugs.com". www.drugs.com. Retrieved 2015-11-28. 

External links[edit]